Salute e Benessere

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent)…

Teva ”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “ Notes ”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the “ Tender Offer ”) to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750%...
Nasdaq GlobeNewswire
20/05/2025

Segra International Acquires Klonetics to Expand Nursery Capacity and Accelerate…

Leveraging Klonetics' existing licenses and infrastructure, Segra plans to expand its nursery capacity and operational capabilities, enriched by Segra's state-of-the-art tissue culture and molecular laboratories. Furthermore, the utilization of Klonetics' flowering capacity will support research and development, cultivar characterization, and performance validation of new genetics.By integrating with Klonetics, Segra will elevate the quality and diversity of cannabis genetics available to...
Nasdaq GlobeNewswire
20/05/2025

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful…

Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline. In addition, Fitch mentions that Teva's focus on optimizing external spend, prioritizing resource allocation, and modernizing its organization is expected to lead to higher operating margins.“We are proud to receive a second consecutive upgrade from Fitch within several months, especially coming on the heels of...
Nasdaq GlobeNewswire
20/05/2025

GENFIT to receive a €26.5 million milestone payment following the approval of…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen's Iqirvo® 1has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC).This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration...
Nasdaq GlobeNewswire
20/05/2025

PCI BIotech: Disclosure of voting rights for Chair of the Board

Hans Peter Bøhn is chair of PCI Biotech's board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr. Bøhn will represent and vote for 10.9 percent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of...
Nasdaq GlobeNewswire
20/05/2025

Roche provides update on FDA Advisory Committee meeting on Columvi combination…

Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the phase III STARGLO study 1,2 There is an urgent need for effective, immediately available therapies that are broadly accessible to people with transplant-ineligible R/R DLBCLThis first-of-its-kind Columvi combination could provide a much-needed, off-the-shelf and fixed-duration treatment option for patients who face poor prognosisThe...
Nasdaq GlobeNewswire
20/05/2025

Alacrita Expands Investor Support Services with Appointment of Lucas Rodriguez…

His appointment supports Alacrita's expanded biotech investment & fundraising advisory services, which integrate scientific, clinical, and commercial expertise to help clients move from capital strategy to effective execution across development and investor-facing priorities. Alacrita offers a flexible and convenient pool of high-caliber consultants with expertise in management and core R&D disciplines, which VC investors can draw upon to help evaluate investment opportunities, support…
PR Newswire
20/05/2025

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 20, 2025 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:976 shares at DKK 962.00, 653 shares at DKK 1,025.00, and 117 shares at DKK 1,050.00.Proceeds to the...
Nasdaq GlobeNewswire
20/05/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of April 30, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (May 20, 2025 - 6:00 pm)– As of April 30, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as...
Nasdaq GlobeNewswire
20/05/2025

Santhera's Shareholders Approve all Board Proposals at Today's Annual General…

Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company's share capital.Approval of the 2024 Annual Report and discharge of corporate bodies The shareholders approved the Annual Report, the annual...
Nasdaq GlobeNewswire
20/05/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – May 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on May 16, 2025, from Atlas Special…
Actusnews Wire
20/05/2025

Clinical Decision Support Systems (CDSS) Market worth US$3.89 billion by 2030…

Browse in-depth TOC on "Clinical Decision Support Systems Market" Browse in-depth TOC on "Clinical Decision Support Systems Market" 300 - Tables55 - Figures350 - Pages By delivery mode,the clinical decision support systems market is divided into on-premises and cloud-based modes. In 2024, the on-premises CDSS segment is estimated to account for the largest share of the clinical decision support systems market. This growth of this segment is primarily due to the growing...
PR Newswire
20/05/2025

Burn Care Market Share to Surpass $4.23 billion, Globally, by 2030 | Exclusive…

Market Overview and Growth Trajectory: Market Overview and Growth Trajectory: Burn Care Market Growth: According to an exhaustive report by The Research Insights, the Burn Care Market is experiencing significant growth, driven by the increased demand because burn injuries continue to rise globally. Burn injuries remain a leading cause of both morbidity and mortality worldwide, especially in low- and middle-income countries that lack sufficient access to healthcare and treatment...
PR Newswire
20/05/2025

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI)…

Follicular lymphoma (FL) is the most common indolent (slow-growing) form of B-cell non-Hodgkin Lymphoma (NHL), accounting for 20% of NHL in the US.1 FL is considered incurable with current standard of care therapies.2 Patients often relapse and with each relapse, the remission and time to next treatment is shorter.3 Patients with r/r FL are in need of additional medical options. "IFLI is dedicated to accelerating the development of innovative treatment options for patients with r/r FL"…
PR Newswire
20/05/2025

Pintuition Validated as a Safe and Reliable Navigation Solution by Large…

"These results further validate the clinical value of Pintuition Surgical Marker Navigation," said Kitty Kempen, Director of Clinical & Medical Affairs at Sirius Medical. "They reinforce our mission to provide intuitive navigation solutions that enhance surgical precision, streamline workflows, and elevate the patient experience." "These results further validate the clinical value of Pintuition Surgical Marker Navigation," saidKitty Kempen, Director of Clinical…
PR Newswire
20/05/2025

InMode Announces Health Canada Certification of the IgniteRF Platform with the…

IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results. Unlike more surgical procedures, IgniteRF treatments do not require extensive surgery or lengthy recovery...
PR Newswire
20/05/2025

myTomorrows Surpasses 15,000 Patient Matches through AI-Powered Platform and…

With over 500,000 clinical trials active worldwide and more than 8,000 drugs in development, timely access to investigational treatments remains a critical challenge for patients. With over500,000 clinical trials active worldwide and more than8,000 drugs in development, timely access to investigational treatments remains a critical challenge for patients. Using a unique combination of expert Patient Navigation services and an AI-driven platform – which automates clinical trial matching...
PR Newswire
20/05/2025

Yili's Breast Milk Innovations Recognized at ESPGHAN 2025

Other groundbreaking discoveries presented by Yili, in collaboration with Tsinghua University, Nanchang University, China Agricultural University, and other institutions, were also a major highlight of the annual meeting. These studies revealed new insights into: how a mother's postpartum emotional state affects infant gut microbiota and early brain development; how a balanced dietary fatty acid profile can enhance lipid metabolism and cognitive function through gut microbiota modulation; and…
PR Newswire
20/05/2025

Philips launches RADIQAL study to generate real-world evidence for new ultra-low…

Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of theRADIQAL...
Nasdaq GlobeNewswire
20/05/2025

Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in…

/2 clinical trial designed to evaluate the use of T-Guard for the treatment of patients with diffuse cutaneous systemic sclerosis (dcSSc), a serious autoimmune disorder with limited treatment options.This open-label, single-arm Phase 1/2 clinical trial (PHIL_TG-01; EU CT: 2024-517283-28-00) aims to assess the safety and preliminary efficacy of T-Guard in early-stage dcSSc patients. The study is planned to enroll 12 adult patients who have been diagnosed within the last three years with dcSSc...
Nasdaq GlobeNewswire
20/05/2025

From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room

VANCOUVER, BC, May 20, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The World Economic Forum recently spotlighted five healthcare breakthroughs, and at the top of the list was artificial intelligence. From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI is no longer an emerging force—it's the engine quietly transforming the entire healthcare ecosystem. Across hospitals, research labs, and digital health platforms…
PR Newswire
20/05/2025

New shares of Bioretec Ltd subscribed with option rights have been registered…

Following the registration of the new shares, the total number of shares in Bioretec is 24,626,474. Following the registration of the new shares, the total number of shares in Bioretec is 24,626,474. The new shares will be issued in the book-entry system on or about tomorrow21 May 2025. The new shares will confer shareholder rights in the company as of their registration on the investors' book-entry accounts. Trading in the new shares is expected to commence on Nasdaq First North Growth...
PR Newswire
20/05/2025

More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and…

Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs: Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical,...
PR Newswire
20/05/2025

Beckley Psytech announces positive topline data from Part 2 of its Phase IIa…

Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours.Data from the core, randomised stage of Beckley Psytech's Phase IIb study of BPL-003 for treatment resistant depression is expected in mid-2025.OXFORD, UNITED KINGDOM – 20 MAY 2025. Beckley...
Nasdaq GlobeNewswire
20/05/2025
Altri  Comunicati